Molecular mechanisms of endocrine disruptors: Interference with the endocrine system activity by Laforgia, Vincenza & Falco, De
 Research Signpost 
 Trivandrum 
 Kerala, India 
 
 
 
 
Endocrine Disruptors and their Effect on Environment and Human Health, 2018: 29-48                                    
ISBN: 978-81-308-0576-4 Editor: Damiano Gustavo Mita 
 
2. Molecular mechanisms of endocrine 
disruptors: Interference with the endocrine 
system activity 
 
Maria De Falco1,2,  Mariana Di Lorenzo1 and Vincenza Laforgia1,2 
1Department of Biology, University Federico II of Naples, Naples, Italy; 2National Laboratory                       
on Endocrine Disruptors of Interuniversity Consortium INBB, Naples, Italy 
 
Abstract. Endocrine disrupting chemicals (EDCs) are an 
heterogeneous group of compounds able to interfere with 
hormonal functions by mimicking the endogenous hormones. This 
feature makes them able to interact with different cellular and 
molecular targets that affect all the biological functions of 
organisms. Many EDCs have a structural similarity with several 
endogenous hormones and this allows them to interact physically 
with specific receptors even though with different binding 
affinities each time. In this review we have collected some of the 
various and manifold molecular mechanisms activated by EDCs. 
Of these, the receptor-mediated pathway prevails; it is based on 
the interaction with estrogen receptors (ERs). However, this is not 
the only way they can use to determine endocrine interference. 
Several in vitro and in vivo studies have shown the existence of 
non-receptor and non-genomic pathways that are much faster and 
trigger a number of signal transduction pathways that control 
multiple cellular functions such as proliferation, differentiation  
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and motility. Finally, several EDCs affect the hypothalamus-pituitary axis and the 
hormonal systems involved in the thyroid and the adrenal glands. Their wide 
presence in the environment and the multiple exposure paths to which we are 
constantly subjected, make EDCs a very wide health problem. Determining the 
specific molecular mechanisms that they are able to activate is an important step in 
trying to reduce the risk associated with their presence in our daily lives. 
 
Introduction 
 
 The endocrine system is formed by different glands producing several 
hormones which are able to regulate metabolism, growth, development and 
reproduction in humans and animals (Witorsch, 2002). Endocrine Disruptor 
Chemicals (EDCs) are exogenous compounds, of natural or synthetic origin, 
that are able to interfere with different hormonal pathways such as 
production, transport, metabolism and action of natural hormones. EDCs can 
act as agonists and/or antagonists of natural hormones. EDCs are 
characterized by multiple mechanisms: they can function in genomic, 
epigenomic or non-genomic manner. In this way, EDCs negatively influence 
homeostasis, reproduction and developmental processes (Sun et al. 2016). 
EDCs are ubiquitously present in the environment because they are used in 
different industrial (industrial chemicals, plastic packaging components) and 
agricultural (pesticides, fungicides, insecticides, herbicides) purposes  
(Nappi et al. 2016). Other than, EDCs are used for the preparation of 
detergents, cosmetics, sun lotion for personal care and in the manufacturing 
of toys. Moreover, they can be presents in the environment as natural 
compounds like phytoestrogens. EDC classification is complicated but in 
general they can be divided in short-lived pollutants and persistent organic 
pollutants (POPs) (Giulivo et al. 2016). The first category includes 
phthalates and bisphenol A, whereas POPs include the organochorine 
pesticides dichlorodiphenyltrichloroethane (DDT) and other industrial 
products as dioxins, flame retardants (Giulivo et al. 2016). Due to their 
whole diffusion in each matrix (sediments, soils, water, atmosphere), human 
exposure to EDCs is unavoidable and can mainly occur through the food 
chain, by the consumption of contaminated tap water and food, by dermal 
exposure and/or by inhalation of volatile compounds and airborne fine and 
ultrafine particulate matter (Nappi et al. 2016). Another important EDC 
peculiarity is their lipophilic nature that allows their persistence in the 
environment other than biomagnification and bioaccumulation processes. 
Morevoer, it is important to consider that animals and humans are exposed to 
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complex mixtures of EDCs. These compounds can have a great complexity 
of mechanism of action, because their can contemporary act on multiple 
signaling pathways and targets (Nappi et al. 2016).  
 Other the way of exposure, particularly important is the consideration of 
the time of in order to evaluate the next impact of EDCs on biological 
systems. Specifically, the fetal life represents a period of special attention, 
since important processes such as organogenesis and tissue differentiation 
must occur through a series of well-regulated molecular, biochemical and 
cellular events (Prusinski et al. 2016). Any perturbation of only one of 
developmental key point can cause adverse effect in the ―tomorrow‖ person. 
It has been demonstrated that environmental exposures during specific 
―window of susceptibility‖ can permanently reprogram normal physiology 
of polluted organisms. In this view, prenatal and early postnatal 
developmental processes are more susceptible to EDC action since each 
minimum change of timing and/or activation/inhibition pathways can alter 
all the other cellular events. However, humans are continuously exposed to 
EDCs daily during all the life, hence all stages of body physiology are 
potential targets of endocrine disruption. Moreover, EDCs differ from other 
environmental pollutants since they are able to function at small doses but 
inducing subtle changes at cellular and tissue levels that finally evoke 
pathophysiological effects (Prusinski et al. 2016). At today, all human body 
systems are negatively influenced by EDCs: cardiovascular system 
(Roseboom 2012), nervous system (Nesan and Kurrasch 2016), reproductive 
system (Crews and McLachlan 2006, Maqbool et al. 2016), digestive system 
(Janesick and Blumberg 2016; Nappi et al. 2016) and obviously endocrine 
system. Moreover, EDCs are linked to carcinogenes, teratogenesis and 
transgenerational inheritance of phenotype (Bernal and Jirtle 2010;    
Prusinski et al. 2016). In the last twenty years, the study of EDCs have 
completely revolutionized the concept of teratological compounds, in fact 
from substances inducing structural abnormalities at birth they have been 
transformed in molecules and/or mixtures of chemicals involved in the 
developmental origin of adult diseases (McLachlan 2016). Among all the 
well known substances acting as teratological compounds, a pioneer of 
EDCs that has contributed to the modification of endocrine disruption view 
in the teratology, was diethylstilbestrol (DES) that for the first time had been 
demonstrated as the cause of transplacental carcinogenesis: DES took by the 
mother during pregnancy was able to induce cancer later in the life of the 
daughters (McLachlan 2016).  
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Multiple compounds for multiple molecular mechanisms 
 
 As written above, EDCs can have many different molecular behaviour 
and they can act on multiple cellular targets. However, the more important 
EDC targets are the nuclear receptors such as estrogen (ER), progesterone 
(PR) and androgen (AR) receptors, steroid (mineralcorticoid, glucocorticoid) 
receptors, thyroid receptors (TR) and peroxisome proliferator-activated 
receptors (PPAR) (Wuttke et al. 2010; Yang et al. 2015; Giulivo et al. 
2016;). Due to the broad involvement of these receptors in many different 
cell and tissue functions, it is evident the attention needed to EDC role in 
biological interference at several points. Recent studies have demonstrated 
that EDCs can also act with membrane receptors like estrogen receptor 
GPER or other ER splice variants. Moreover, EDCs interfere with enzyme 
activity such as hormone metabolizing enzymes like aromatase (Sanderson, 
2006), 5-reductase (Kalfa et al. 2009), 3-hydroxysteroid dehydrogenase                        
(Ye et al. 2011) and 11-hydroxysteroid dehydrogenases (Odermatt et al. 
2006; Guo et al. 2012; Giulivo et al. 2016).  
 Among EDCs there are numerous compounds that exert an estrogenic 
effects. It is well known that estrogen is a female hormone but its role is not 
only to regulate female reproductive cycle but also to influence non 
reproductive organs regulating lipid metabolism, protein synthesis and 
behaviour (Kiyama and Wada-Kiyama 2015). So, estrogenic chemicals that 
mimick this endogenous female hormone are able to interfere with normal 
body homeostasis through different mechanisms. In fact, estrogenic 
signaling can be divided in intracellular and extracellular mechanism. The 
intracellular pathway involves genomic activation such as transcription of 
specific target genes, and non-genomic pathway through the activation of 
transduction signals mediated by membrane receptors (Kiyama and                 
Wada-Kiyama 2015). The extracellular pathway, on the contrary, involves 
other hormones, growth factors and cytokines (Kiyama and Wada-Kiyama 
2015). It is very difficult to identify all chemicals that act as estrogenic 
compounds since other EDCs can have multiple effects including estrogenic 
actions (For a list of several estrogenic chemicals, see Kiyama and                   
Wada-Kiyama 2015 review). Considering the estrogenic compounds, it is 
important to specify that they have contradictory effects since they can 
behave as estrogen or anti-estrogen, agonist or antagonist of ERs. Often, it 
has been pointed out a biphasic activity, better depending of the dose they 
show an estrogenic or antiestrogenic activity. Anyway, they can show 
different cellular pathways (Kiyama and Wada-Kiyama 2015). This 
mechanism of action is often shared among different EDCs.  
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 In order to describe a view of different molecular mechanisms, we have 
subdivided their targets in genomic, non genomic and non-receptorial 
pathways. 
 
Genomic pathway 
 
 The genomic pathway is the main target of EDCs. This pathway starts 
with the binding of chemicals with the nuclear estrogen receptors (ERs). 
There are two different ERs: ERα and ERβ, both involved as transducer. 
They are encoded by different genes, respectively ESR1 located at 6q25.1 
and ESR2 located at 14q23.2-q23.3 on human chromosomes. Even so, the 
receptor proteins share a common structural organization based on the 
presence of three functional domains: the A/B domain at the N-terminal 
region, involved in the transcriptional activation of ER target genes; the                 
C domain responsible for the receptor dimerization and DNA binding; the 
E/F domain at the C-terminal region involved in the ligand binding, nuclear 
translocation and transactivation of target gene expression (Nilsson et al. 
2001; Kiyama and Wada-Kiyama 2015). Both ESR1 and ESR2 show splice 
variants that are responsible of differences in the expression at cell or tissue 
level, in the specificity and/or affinity for a ligand, in the localization and 
function in the cells (Taylor et al. 2010; Kiyama and Wada-Kiyama 2015). 
Co-regulators and other transcriptional factors, such as Sp1 and AP1, are 
often needed for the transactivation of target genes (Kiyama and                  
Wada-Kiyama 2015). The complex (endogenous or not) ligand - ER binds 
the DNA at specific site acting as transcription factor in order to up-regulate 
or down-regulate the transcription of target genes (generally bringing the 
Estrogen-Responsive-Elements) (Kiyama and Wada-Kiyama 2015). The 
change in ER conformation depending on the ligand bound, renders ERs 
more or less prone to the transcriptional coactivators or corepressors 
recognition (Acconcia et al. 2015). Very large amount of estrogenic 
chemicals (fungicides, herbicides, insecticides, several pharmaceutical 
estrogens, plasticizer, pollutants) use ERs as dealer to induce endocrine 
interference (Kiyama and Wada-Kiyama 2015). Among these, BPA has 
structural features that confer it the ability to bind to the both ERα and ERβ 
(Bolli et al. 2008; Bolli et al. 2010; Acconcia et al. 2015). BPA binding to 
ERs produces a displacement of α-helices of LBD of ERα due to a not 
proper accommodation in the hormone-binding site; so BPA can function as 
ERα agonist. On the contrary BPA is not able to bind the LBD of ERβ, 
acting as antagonist (Ascenzi et al. 2006; Acconcia et al. 2015). These 
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differences in the binding of the two ERs induce a varied regulatory activity 
on gene expression (Acconcia et al. 2015). Many other EDCs are able to 
bind ERs. It has been demonstrated that nonylphenol (NP) is able to induce 
cytoplasm to nucleus translocation of ERα but not ERβ in human epithelial 
prostate cells (Forte et al. 2016). This translocation induced ERα activation 
of transcription of specific genes such as cyclin D1 and ki67 that allow cell 
proliferation (Forte et al. 2016). Recently, another nuclear receptor family 
has been identified as part of estrogen signaling. This family includes some 
nuclear estrogen-related receptor such as ERRα, ERRβ and ERRγ. These 
―alternative‖ receptors act as ligand-dependent transcription factors but their 
natural ligand is still unknown. Several compounds prefer ERR pathways 
such as genistein and resveratrol, as well as chlordane, diethylstilbestrol and 
toxaphene that are ERR antagonists. In some case it is possible a crosstalk 
between ER and ERRs as demonstrated for resveratrol (Kiyama and                
Wada-Kiyama 2015). That’s why nuclear receptor pathway is more complex 
and interlaced. 
 
Non-genomic pathway 
 
 Estrogen or xenoestrogens can also bind to the membrane receptors 
stimulating signaling cascade through different protein involvement. 
Generally, the non-genomic pathway is very fast and rapidly occurs. 
Canonical ERα and ERβ can translocate to the membrane after the 
modification. Here, they bind to caveolin-1 after palmitoylation, after that 
they are translocated to the membrane and anchored as a dimer (Soltysik and 
Czekaj 2013; Kiyama and Wada-Kiyama 2015). It has been shown that this 
pathway is used by the cells to rapidly respond to hypothalamic stimulation 
(Micevych and Kelly 2012; Kiyama and Wada-Kiyama 2015). Endogenous 
estradiol (E2) activates ERα-mediated extracellular regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK) and phosphatidyl-
inositol-3-kinase/AKT (PI3K/AKT) pathways, as well as the ERβ-mediated 
p38/MAPK signaling (Acconcia and Marino 2011; Acconcia et al. 2015). It 
has been demonstrated that xenoestrogenic compounds such as BPA can 
activate ERK/MAPK and AKT phosphorylation (Bolli et al. 2008; Marino   
et al. 2012; Acconcia et al. 2015). Another EDC such as Arsenic (As) is able 
to interfere with estrogen signaling pathways (Watson and Yager 2007;              
Bae-Jump et al. 2008; Chatterjee and Chatterji 2010; Sun et al. 2016). 
Particularly, it has been shown that As interacts with the MAPK pathway 
(mitogen-activated protein kinase), which plays a crucial role in different 
cell functions such as cell growth, differentiation, survival, and death 
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(Chatterjee and Chetterji 2010; Sun et al. 2016). Moreover, it has been 
demonstrated that As suppresses the interaction of ERs with some 
transcription factors like Sp-1, AP-1 and NF-κB (Watson and Yager 2007; 
Sun et al. 2016).  
 Different membrane ERs (mERs) have already been identified such as 
G-protein coupled estrogen receptor (GPER). The mERs GPER, previously 
known as G-protein-coupled receptor 30 (GPR30), is encoded by the GPER 
gene located at chromosome 7p22.3. GPER is a 7-membran-spanning 
protein highly expressed in the hypothalamus, pituitary gland, adrenal 
medulla, renal pelvis and ovary (Hazell et al. 2009; Soltysik and Czekaj 
2013; Kiyama and Wada-Kiyama 2015). GPER shows a high affinity for the 
endogenous estrogens and other hormones such as aldosterone (Kiyama and 
Wada-Kiyama 2015). GPER can be located at the membrane of endoplasmic 
reticulum, Golgi apparatus and can be also present in the nucleus (Soltysik 
and Czekaj 2013; Kiyama and Wada-Kiyama 2015). GPER activation 
induces rapid non-genomic signaling (Kiyama and Wada-Kiyama 2015). 
Different xenoestrogenic compounds have been demonstrated bind to the 
GPER such as BPA, diethylstilbestrol, genistein, NP and many others 
(Kiyama and Wada-Kiyama 2015). These compunds act as agonists to the 
GPER. Moreover, it has been demonstrated that GPER in involved in the 
signaling pathways mediated by other receptors like serotonin 1A receptor 
(Li et al. 2013c; Kiyama and Wada-Kiyama 2015). Particularly, it acts 
inhibiting serotonin 1A receptor (Xu et al. 2009; McAllister et al. 2012; 
Akama et al. 2013; Kiyama and Wada-Kiyama 2015). Moreover, GPER 
crosstalks with other signaling pathways involved in different cell functions 
such as proliferation (Ma et al. 2014), migration (Li et al. 2014a), collagen 
expression (Li et al. 2013a), NO synthesis (Rowlands et al. 2011), and 
inflammatory response (Luo et al. 2012; Santolla et al. 2014; Kiyama and 
Wada-Kiyama 2015). It seems evident that due to involvement of GPER in 
many different cell pathways involved in any stage of proliferation, 
differentiation and migration, that all the chemicals able to bind this receptor 
can deeply interfere with many cell and tissue important processes. 
 Other receptors, such as estrogen-related receptors (ERRs) that are 
variants of ERα and ERβ (for example ER-X and ER-α36) have been 
recently identified showing the broad complexity of estrogen responsive 
signaling (Kiyama and Wada-Kiyama 2015). Specifically, ER-X is a ERα 
splice variant; it is a 62-63 kDa membrane protein (Soltysik and Czekaj 
2013; Kiyama and Wada-Kiyama 2015). Binding of estrogen to ER-X is 
associated in particular to the brain, uterus and heart functions. It has been 
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demonstrated that after binding, ER-X activate MAPK and ERK signaling 
(Toran-Allerand et al. 2002; Toran-Allerand et al. 2005; Ullrich et al. 2008; 
Kiyama and Wada-Kiyama 2015). Another ERα splice variant is ER-α36 is 
located at the membrane. This receptor lacks both AF-1 and AF-2 domais 
but present DNA-binding domain and partial ligand domain. It has been 
shown that ER-α36 is able to inibit both ERα and ERβ in a dominant-
negative manner. This ability allows it to be involved in different 
carcinogenesis pathways such as testosterone carcinogenesis (Lin et al. 
2009) and breast cancer (Rao et al. 2011; Kiyama and Wada-Kiyama 2015). 
Different cascade proteins can activated by ER-α36 such as MAPK/ERK, 
Akt, and c-SRC (Kang et al. 2011; Zhang et al. 2014c; Wang et al. 2013b; 
Kiyama and Wada-Kiyama 2015). 
 Both genomic and non-genomic pathways can be considered as direct 
signaling mechanisms that differently can induce many functional outcomes 
such as apoptosis, cell growth, differentiation, inflammation and 
carcinogenesis (Kiyama and Wada-Kiyama 2015). However, each pathway 
can influence other cellular outcomes by crosstalk and/or bypassing. 
Moreover, the direct signaling mechanisms also induce the secretion of 
autocrine/paracrine or endocrine factors enlarging the range of targets 
involved.  
 
Epigenetic pathways 
 
 EDCs can also act through epigenetic mechanisms. Epigenetic 
mechanisms are particularly important to address the potential health effects 
of lower-level exposures within the general population; moreover it is useful 
to explain how EDC exposure during the development can cause adverse 
effects in the adult (Prusinski et al. 2016). It has been shown, for example, 
that genistein is able to induce epigenetic changes of non-genomic estrogen 
receptor (ER) signaling through the activation of the PI3K/AKT pathway 
(Prusinski et al. 2016). This phosphorylates histone methyltransferase 
Enhancer of Zeste Homolog 2 (EZH2), a potent epigenetic regulator of gene 
expression (Sandovici et al. 2013). Finally, this epigenetic pathway increases 
the overall expression of estrogen-responsive genes (Cook et al. 2005; 
Prusinski et al. 2016). Likewise, also BPA increases EZH2 that in turn 
increases histone H3 trimethylation at lysine 27 (Doherty et al. 2010; 
Santangeli et al. 2017). Furthermore, BPA was demonstrated to alter 
methyltransferase 1 and 3A which are epigenetic regulators of expression of 
genes encoding estrogen receptors (Kundakovic et al. 2013; Santangeli et al. 
2017). BPA induces hypermethylation of estrogen promoter region in rat 
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testis (Doshi et al. 2011; Santangeli et al. 2017). Other studies have shown 
that BPA strongly increases the expression of the secretaglobin gene, 
Scgb2a1, by way of the increased enrichment of acetylated H3K9 and 
hypomethylation of DNA for a CpG island upstream of the transcription start 
site of Scgb2a1 (Wong et al. 2015; Prusinski et al. 2016). SCGB2A1 is being 
an interesting marker of carcinogenesis, since its gene and protein 
overexpression is linked to endometrial, breast and lung cancers (Li and 
Richardson 2009; Prusinski et al. 2016). 
 
Non receptorial pathways 
 
 Recently, different studies highlight other non nuclear receptor mediated 
pathways involved in estrogenic and xenoestrogenic actions. In fact, it is 
well known that natural hormones and xenoestrogens can also act by 
enzymatic and binding protein pathways (Mueller and Korach 2001;              
Sheikh et al. 2017). Particularly, sex steroids interact with plasma sex 
hormone-binding globulin (SHBG) that is a circulatory protein secreted by 
liver important in maintaining the balance between bioavalable and not 
avalaible hormones (Anderson 1974; Sheikh et al. 2017). Particularly, it has 
been demonstrated that the free portion of steroid hormones represents a 
small percentage, about 1-3% of the total steroids. Despite this low amount 
represents the bioactive portion for the target tissues (Hammond, 2011; 
Laurent and Vanderschueren 2014; Sheikh et al. 2017). The SHBG binds 
both androgens and estrogens with nanomolar affinity. SHBG has two 
subunits each containing two laminin G-like domains: the N-terminal 
domain presents the steroid-binding pocket and calcium and zinc binding 
sites; the C-terminal domain shows residues for glycosylation (Hammond 
2011; Sheikh et al. 2017). It regulates hormonal free portion able to bind 
receptors that is important in clinical practice. Moreover, SHBG influences 
hormonal metabolic clearance (Hammond 2011; Sheikh et al. 2017). 
Alteration of SHBG function and/or amount has been associated with 
various human diseases such as ovarian dysfunctions, male and female 
infertility, endometrial cancer, diabetes, cardiovascular diseases                   
(Cherkasov et al. 2005; Sheikh et al. 2017). Many different EDCs can bind 
SHBG, among these some alkylphenols such as BPA, NP, octylphenol (OP) 
have been shown binding ability (Dechaud et al., 1999; Jury et al., 2000; 
Cherkasov et al., 2008; Hong et al., 2015; Sheikh et al. 2017). Recently, it 
has been demonstrated that BPA, NP and OP have high structural similarity 
with endogenous hormones and for this they can strongly bind SHBG 
(Sheikh et al. 2017). Among three alkylphenols Sheikh et colleagues (2017) 
have seen that NP is the more potent endocrine disruptor of androgen and 
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estrogen signaling since it shows the most high binding affinity with SHBG 
(Sheikh et al. 2017). Binding of xenoestrogens to SGBG displaces 
endogenous testosterone and estradiol from SHBG steroid pocket in native 
plasma from men and women (Dechaud et al. 1999; Sheikh et al. 2017). In 
an other study, 125 structurally diverse compounds have been tested in 
competitive binding assay for SHBG and it has been shown that BPA, OP, 
and NP have a potential competing function (Hong et al. 2015; Sheikh et al. 
2017). Xenoestrogenic binding to SHBG induce a lower clearance rate that 
allows a major accumulation of EDCs in the body. Moreover, in children 
during the prepubertal period (Apter et al., 1984; Belgorosky and Rivarola, 
1986) and in women during pregnancy (Anderson 1974), SHBG levels are 
higher whereas testosterone and estradiol concentrations remain lower. 
Under such conditions, BPA, NP and OP ability to bing SHBG may affect 
the metabolism and tissue availability of natural steroids (Sheikh et al. 
2017). This ―new‖ EDC molecular target of endocrine disruption open a 
broad scenario of interference with steroid homeostasis in the human body. 
 
EDCs and hypothalamus-pituitary axis 
 
Thyroid gland 
 
 Another important field to consider in EDC pollution is the 
involvement and activation of other hormonal pathways, such as thyroid 
and adrenal glands. EDCs can impair thyroid system through different 
mechanisms: disruption of TH serum transporters such as transthyretin 
(TTR) and thyroxine-binding globulin (TBG), aberrant binding to TH 
nuclear receptors, or disruption of TH-metabolizing enzymes such as 
deiodinases (DIO) and sulfotransferase (SULT) (Aufmkolk et al. 1986; 
Meerts et al. 2000; Schmutzler et al. 2004; Kitamura et al. 2008; Kojima       
et al. 2009; Szabo et al. 2009; Butt et al. 2011; Butt and Stapleton 2013; 
Leonetti et al. 2016). Particularly, it has been demonstrated that different 
EDCs are able to negatively influence thyroid hormone levels (Zhou et al. 
2002; Sciarrillo et al. 2010; Noyes et al. 2013; de Coch et al. 2014; 
Eisenreich and Rowe 2014; Yost et al. 2016). Several studies have 
demonstrated that prenatal exposure to thyroid hormone endocrine 
disruptors affect birth weight, can cause preterm births, other than affect 
the glucose and lipid metabolism (Molehin et al. 2016; Shah-Kulkarni      
et al. 2016). Infact, THs are known to be particularly important for fetal 
growth and development (Costa et al. 2014; Leonetti et al. 2016). Different 
interference pathways can be activated in alteration of thyroid functions. 
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For example, it has been hypothesized that perfluorinated compounds 
(PFCs) may increase the hepatic production of TBG (Knox et al. 2011). 
Other PFCs like perfluorooctane sulfonate (PFOS) may increase the 
thyroidal conversion of T4 to T3 via type 1 deiodinase (Yu et al. 2009; 
Shah-Kulkarni et al. 2016). Polybrominated diphenylethers (PBDEs) and 
other halogenated compounds (Butt et al. 2011; Butt and Stapleton 2013; 
Leonetti et al. 2016) are able to inhibit the activities of TH-metabolizing 
enzymes so impacting the placental TH concentrations and fetal TH 
delivery (Leonetti et al. 2016). Other compounds such as As alters thyroid 
hormone production. Particularly, it has been shown that after consuming 
diet containing As for 15 weeks, plasma levels of T3 and T4 are decreased 
while the ratios of T4/T3 are increased (Meltzer et al. 2002; Sun et al. 
2016). Moreover, Ciarrocca et al. (2012) have shown an increase of the 
levels of thyroid stimulating hormone (TSH) and thyroglobulin and a 
decrease of free T4 and T3 contents (Ciarrocca et al. 2012; Sun et al. 
2016). Opposite effects were seen in rats where feeding food containing As 
increases T3 levels and decreases T4/T3 ratios (Glattre et al. 1995). As 
thyreotoxicity is related to alteration of TR-related gene expression. 
Particularly, AsIII inhibites the activity of thyroid peroxidase, a major 
enzyme involved in the synthesis of T4 and T3 (Palazzolo and Jansen 
2008; Sun et al. 2016). Thyroid disruption has been demonstrated also in 
different animal models. It has been shown that PBDEs are able to disrupt 
thyroid hormone signaling in Xenopus laevis tadpole (Yost et al. 2016). 
Specifically, Yost and colleagues have demonstrated that 2,2’,4,4’-
tetrabomodiphenyl ether (BDE-47) specifically alterate transcriptomic 
expression of thyroid hormone-related genes (Yost et al. 2016). BDE-47 
reduces expression of trα, trβ and tshβ and decreases thyroid hormone 
plasma levels (Yost et al. 2016). Moreover, BDE-47 influences also 
thyroid hormone transport; in fact it suppresses expression of two thyroid 
hormone transporters mct8 and oatp1c1 (Yost et al. 2016). In fish, AsIII 
significantly increases the levels of T4 (Sun et al. 2015; Sun et al. 2016). 
On the contrary, in Podarcis sicula lizards, NP induced a significant 
decrease of TSH, T4 and T3 plasma levels and affected histological 
features of lizard thyroid (Sciarrillo et al. 2010). 
 
Adrenal gland 
 
 Another important organ in the control of endocrine homeostasis is the 
adrenal gland. Adrenal gland plays a role in the body response mechanisms 
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to stress, maintaining the homeostasis of the organism (De Falco et al. 2014). 
Despite its relevance in the body physiology, relatively few studies have 
investigated the possible/existing links between endocrine disruptors and the 
HPA axis (De Falco et al. 2007; De Falco et al. 2010). Recently, it has been 
demonstrated that As significantly increases ACTH and corticosterone levels 
in rodents (Jana et al. 2006; Sun et al. 2016). Particularly, it has been shown 
that As is able to reduce levels of corticotropin-releasing factor receptor 1 
and to potentiate binding between serotonin and serotonin                                     
5-hydroxytriptamine receptor (Martinez et al. 2008). Moreover, As acts on 
glucocorticoid receptors (GRs). Specifically, it has been demonstrated that 
AsIII can modify GR activity blocking steroid binding to GRs (Lopez et al. 
1990; Kaltreider et al. 2001; Sun et al. 2016). Recently, Ahir et al. (2013) 
have demonstrated that AsIII has a biphasic effect on GR function depending 
of its dose. At low dose, AsIII enhances glucocorticoid induction of                     
GR-regulated genes, whereas at high dose it disrupts GR gene transcription 
interfering with hormone receptor binding (Ahir et al. 2013; Sun et al. 2016). 
Other EDCs are able to interact with GR system. For example, it has been 
demonstrated that polychlorinated biphenyls (PCBs) downregulate brain GR 
expression in fish (Aluru et al. 2004; Nesan and Kurrasch 2016). Other 
compounds have seen to act on HPA axis. Among EDCs, NP was shown to 
strongly stimulate the whole HPA axis inducing a time-dependent 
stimulation of CRF, ACTH and corticosterone release in reptile bioindicator 
Podarcis sicula lizards (De Falco et al. 2014). Moreover, NP was able to 
induce histological changes of adrenal glands with the presence of totally 
degranulated chromaffin cells (De Falco et al. 2014). Another class of potent 
environmental pollutant are dioxins that comprises 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). This compound has shown to reduce 
CRH mRNA in hypothalamus of monkeys (Shridhar et al. 2001; Nesan and 
Kurrasch 2016).  
 
Conclusion 
 
 EDCs are compounds of different chemical nature and are widely 
disseminated in the environment in which we live. This causes the exposure 
of human and animal populations to occur at any time of life and at different 
doses. One characteristic of EDCs is their ability to act at very low 
concentrations, interacting with hormone systems and altering the 
homeostasis of different organs and systems. It is also evident that a precise 
and unambiguous classification is practically impossible since many of them 
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have biphasic behaviors and are capable of activating different molecular 
pathways depending on the cellular system considered. This particular 
feature focuses on the behavior of EDCs that we are constantly exposed to in 
which individual compounds may be present, each with different activity, 
which in combination can trigger synergies that lead to complete and 
profound endocrine destruction and all systems connected to it. For this 
reason, the understanding of the molecular mechanisms that EDCs can 
activate is of paramount importance to orient themselves in the endocrine 
interference they have determined and to try to stem the large amount of 
related pathologies. 
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